drugset / Trial / NCT01752023
A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.
RandomizedParallel-groupOpen-labelTreatment
Summary
Response rates. Changes in tumor blood flow.
Timeline
- Start
- 2013-03
- Primary completion
- 2014-04
- Completion
- 2014-04
Outcome
Outcome not reported
Stopped (Enrollment): “Low Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SUBATM-itraconazole | Unknown | 200 mg | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |